- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2023-02-27
2027-06-30
2028-01-15
30
NCT05743049
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
OBSERVATIONAL
Collection of Circulating Biomarkers in Pancreatic Cancer
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
N/A
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2023-02-10 | N/A | 2025-03-06 |
2023-02-22 | N/A | 2025-03-10 |
2023-02-24 | N/A | 2025-03 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : Blood specimens Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma. | OTHER: Obtaining blood for analysis of various circulating biomarkers
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use. | Through study completion, an average of 1 year |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response. | Through study completion, an average of 1 year | |
| To integrate the data and specimens to permit the most informative clinical-biologic research platform. | Through study completion, an average of 1 year |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Liudmila Mazaleuskaya, PhD Phone Number: 267-455-9141 Email: mazali@pennmedicine.upenn.edu |
Study Contact Backup Name: Mark O'Hara, MD Phone Number: 215-360-0919 Email: Mark.OHara@pennmedicine.upenn.edu |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
